N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=225 Vitamin D and Vascular Health in Children
Obesity · Vitamin D Deficiency
Primary: Flow-mediated Dilation (FMD) Percentage — 7.61; 8.27; 7.31 percentage of baseline dilation — p=0.88
N/A N=125 Non-invasive Computer-Aided Phenotyping of Vasculopathy
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
N/A N=16 Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm
Subclavian Steal
Primary: Change of Subclavian Flow to Normal Flow Pattern During Cuff Test — 0; 2 participants
N/A N=91 Microvascular Blood Flow in Sickle Cell Anemia
Sickle Cell Disease · Sickle Cell Anemia
Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change
Phase 2 N=15 Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation
Phase 3 N=83 Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
Vascular Diseases
Primary: Number of Vessel Segments Visualized With Diagnostic Quality — 8.10; 8.33; 8.03; 8.33 vessel segments
N/A N=338 Vascular Risk After Kidney Transplantation
Cardiovascular Disease · Chronic Kidney Disease · Diabetes
Primary: Carotid Intima Media Thickness (CIMT) — 0.044 millimeters (mm)
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
N/A N=12,012 Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study
Stroke
Primary: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis Confirmed by Vascular Ultrasonography — 96; 1063; 826; 241 artery numbers
N/A N=125 Vitamin D, Insulin Resistance, and Cardiovascular Disease
Vitamin D Deficiency · Insulin Resistance · Type 2 Diabetes Mellitus
Primary: Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP) — 126.6; 131.1; 79.2; 78.9 mm Hg
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
N/A N=99 Effects of Walking and Heating on Vascular Function in Diabetic Patients
Type 2 Diabetes Mellitus · Obesity
Primary: Insulin-stimulated Leg Blood Flow Calculated as Percent Change (t0, t60) — 133.6; 8.92 percentage change
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
Phase 3 N=24 Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Glygocalyx Integrity - Perfused Boundary Region — 0.11; -0.16 Delta micrometers (mcm)
Phase 4 N=70 Vascular Inflammation in Psoriasis - Apremilast
Psoriasis · Cardiovascular Diseases
Primary: Change in Total Vascular Inflammation of the Aorta as Measured by FDG-PET/CT Between Baseline and Week 16. — -0.017 ratio — p=0.612
Phase 4 N=42 Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)
Renal Insufficiency, Chronic
Primary: Change in Flow-mediated Dilation (FMD) — 1.1; -0.9 change in percent flow-mediated dilation
N/A N=20 Sex Differences in Vascular Responses to Exercise
Aging
Primary: Change in FMD in Response to Chronic HIIT — 0.11; 0.57; 0.81; 0.10 % flow mediated dilation
N/A N=48 Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Phase 4 N=43 Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -0.1015; 0.1442; -0.0151 TBR max — p=0.0012
N/A N=130 Effect of Vitamin D3 on Vascular Function
Vitamin D Deficiency
Primary: Pulse Wave Velocity for Vascular Stiffness — 29.3; 27.6 m/s
N/A N=82 Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)
Vertebrobasilar Insufficiency · Ischemic Attack, Transient · Cerebrovascular Disorder
Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants
N/A N=89 Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People
HIV Infection
Primary: Endothelial Function (Brachial Artery Reactivity) — 3.98; 3.37 percent dilation — p=0.10
N/A N=41 Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo
Chronic Kidney Disease
Primary: Change in Circulating ICAM-1 Shown by Absolute Values at Baseline, Day 28 and Day 56 — 707; 701; 679; 627 nanogram/ml — p=>0.05
N/A N=34 Vasculera in Participants With Lipedema
Lipedema
Primary: Change in Weight From Baseline — 0.340 kilograms — p=0.473
N/A N=23 Long Sleep Duration and Vascular Function
Sleep
Primary: Change From Wake in Central Aortic Pulse Pressure After 11 Hours in Bed — -1.5; 0.5 mm Hg — p=0.36
N/A N=202 Dietary Intervention and Vascular Function
Cardiovascular Disease
Primary: Percent Change in Flow Mediated Dilatation (FMD) — -0.39; -0.07; -0.08 post-occlusion diameter change as % — p=0.238
N/A N=52 VASCADE ANTEGRADE-PVD Post-Market Registry
Surgical Wound
Primary: Time to Hemostasis (TTH) — 5.87 minutes
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA